On May 25, 2023, Verastem, Inc. announced an update from its international phase 2 RAMP 201 trial evaluating avutometinib defactinib in recurrent low-grade serous ovarian cancer, regardless of KRAS status. These data, which will be presented at the American Society of Clinical Oncology Annual Meeting, build on the Breakthrough Therapy Designation granted by the U.S. Food and Drug Administration (FDA) for the combination in recurrent LGSOC. The Company plans to include mature data from RAMP 201, the Verastem sponsored clinical trial, and the investigator-sponsored FRAME study to support filing for accelerated approval.

The Company is finalizing the design of a randomized confirmatory trial with the FDA, which is planned to begin in the second half of 2023. Verastem Oncology is currently conducting clinical trials with its RAF/MEK clamp avutometinib in RAS pathway-driven tumors as part of its (Raf And Mek Program). Supported by the Therapeutic Accelerator Award" Verastem Oncology received from PanCAN, the Company is conducting RAMP 205, a Phase 1b/2 clinical trial evaluating avutometinIB and defactinib with gemcitabine/nab-paclitaxel in patients with front-line metastatic pancreatic cancer.

The GOG Foundation is multi-disciplinary in its approach to clinical trials, and includes gynecologic oncologists, medical oncologists, pathologists, radiation oncologists, oncology nurses, biostatisticians (including those with expertise in bioinformatics), basic scientists, quality of life experts, data managers, and administrative personnel.